RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-08-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ulncarcinomaacutepriorbevacizumab
  Phrases that lowered it: malestemtransplantationcolitisbowel
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 23.2% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 123469 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 90.7% (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 15547 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer NCT02982694 · started 2017 · scored riskier than 83% of active trials terminated
• FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients NCT03721653 · started 2018 · scored riskier than 80% of active trials completed
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma NCT03274258 · started 2018 · scored riskier than 75% of active trials terminated
• NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer NCT03832621 · started 2019 · scored riskier than 74% of active trials completed
• BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC NCT03791398 · started 2019 · scored riskier than 97% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.